Argenx scraps Sjogren's trial after futility review
Argenx unexpectedly ended a Vyvgart study in Sjogren's disease after an independent monitoring committee said the trial appeared futile. Shares fell 11.8% to 818.63 in morning trading.
Argenx unexpectedly ended a Vyvgart study in Sjogren's disease after an independent monitoring committee said the trial appeared futile. Shares fell 11.8% to 818.63 in morning trading.